Clinical Trial Update: A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing siltuximab plus best supportive care to placebo plus best supportive care in anemic patients with IPSS low- or intermediate-1-risk mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2014-09-29